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Antitumor chemotherapy remains one of the most important challenge of the medicinal
chemistry. Emerging research in chemotherapy is focused on exploiting the biochemical
differences between cancer cell and normal cell metabolism in order to reduce
the side effects and increase antitumor therapy efficacy. The higher mitochondrial
transmembrane potential of cancer cells compared to not-transformed cells favors
the intra-mitochondrial accumulation of cationic drugs in the former. This feature
could be exploited to allow selective delivery of antineoplastic drugs to the cancer
cells. In this work we designed and synthetized phenol derivatives joined to the
triphenylphosphonium (TPP) cation, a well-known vector for mitochondrial targeting.
Two designed phenol TPP-derivatives 1 and 2 show remarkable cytotoxic activity
against different cancer cell lines, but were less toxic against normal cells. The differential
cytotoxicity relied on the higher mitochondrial biogenesis and oxidative-phosphorylation
metabolism of the former. By reducing mitochondrial mass and energetic metabolism,
and increasing at the same time the levels of intra-mitochondrial reactive oxygen
species, phenol TPP-derivatives 1 and 2 induced mitochondria depolarization and
triggered a caspase 9/3-mediated apoptosis, limited to cancer cells. This work provides
the rationale to further develop phenol TPP-derivatives targeting mitochondria as new
and selective anticancer tools.
Keywords: triphenylphosphonium cation, phenols, cancer mitochondrial biogenesis, cancer mitochondrial
energy metabolism, mitochondrial-dependent apoptosis
INTRODUCTION
The vast majority of chemotherapy drugs targets macromolecules important for cell survival and
proliferation, such as DNA-replication machinery and cytoskeleton structures. While this approach
effectively kills cancer cells, it also affects rapidly growing normal cells producing several toxic side
effects. Emerging research in chemotherapy is focused on exploiting the biochemical differences
Abbreviations: AMC, 7-amino-4-methylcoumarin; ANOVA, analysis of variance; BSA, bovine serum albumin; COX-I,
cytochrome c oxidase/complex IV; HMM, human malignant mesothelioma; HMC, human mesothelial cells; LC-ESI-
MS, liquid chromatography-electrospray ionization-tandem mass spectrometry; LDH, lactate dehydrogenase; MitoTempol,
(2-(2,2,6,6-Tetramethylpiperidin-1-oxyl-4-ylamino)-2-oxoethyl)triphenylphosphonium chloride; PBS, phosphate buffered
saline; ROS, reactive oxygen species; SDH-A, succinate dehydrogenase-A; SDS–PAGE, sodium dodecyl sulfate –
polyacrylamide gel electrophoresis; TPMP, methyltriphenylphosphonium chloride; TPP, triphenylphosphonium.
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between cancer cell and normal cell metabolism in order to
increase the ratio between anti-tumor benefits and undesirable
side effects (Hsu and Sabatini, 2008).
A key metabolic change occurring during neoplastic
transformation is the increased energetic demand, paralleled by
the shift from oxidative phosphorylation to aerobic glycolysis (the
Warburg effect) (Warburg, 1956). Despite it has been generally
accepted that most solid tumors obtain fuel from aerobic
glycolysis, the role of mitochondrial oxidative metabolism
has been recently re-evaluated as a key contributor in tumor
growth and progression (Trotta and Chipuk, 2017). For instance,
a functionally active oxidative mitochondrial metabolism
promotes tumorigenesis, cell migration, metastasis (Caino et al.,
2015; García-Ledo et al., 2017), and drug resistance (Riganti
et al., 2015a; Buondonno et al., 2016). By contrast, impairing
mitochondria energetic metabolism and ATP synthesis, may
reduce cancer cell proliferation and invasion, and trigger
apoptosis (Trotta and Chipuk, 2017). For this reason, targeting
tumor cells mitochondria and impairing mitochondria energetic
metabolism became one of the most promising strategy in
the antitumor therapy (Wallace, 2012; Riganti et al., 2015a;
Weinberg and Chandel, 2015; Buondonno et al., 2016; Refaat
et al., 2017).
Metabolically active mitochondria have highly negative
membrane potential. Charged molecules are generally unable to
cross cell membranes without the aid of transporter proteins,
due to the large activation energies associated with removal
of associated water molecules. The delocalization of charge
across the large lipophilic surface of organic cations significantly
lowers this energy requirement, facilitating passage across
lipid membranes (Murphy, 2008). Thus, TPP cation, which
easily passes through cellular membrane and accumulates in
mitochondria, has been used as a targeting vector for the
mitochondrial drug delivery (Rideout et al., 1989; Bergeron et al.,
2009). Enhanced accumulation of cationic drugs in the solid
tumors, when compared to their normal counterparts, has been
attributed to the higher (i.e., more negative inside) mitochondrial
transmembrane potential of cancer cells compared to normal
cells (Modica-Napolitano and Aprille, 2001). This feature could
be exploited to allow selective delivery of antineoplastic drugs to
the tumor cell.
The antitumor activity of TPP salts was reported for the first
time in 1978 during the routine screening of some synthetic
intermediates (Dubois et al., 1978). More recently, some TPP
salts were reported to show anti-proliferative activity against
cancer cell lines (Rideout et al., 1989; Manetta et al., 1996). These
studies indicated that TPP salts could selectively accumulate in
cancer cells and TPP itself is not cytotoxic. The recent study
of different TPP salts, which screened 40000 candidates, has
individuated three molecules endorsed with antitumor activity in
the low micromolar range (Millard et al., 2010). Authors have
synthetized a number of structural analogs of three molecules,
but coherent structure activity relationship between them was
not identified: the only cytotoxic mechanisms proposed was
the inhibition of oxygen consumption, leading to increased free
radical production and consequent apoptosis (Millard et al.,
2010).
Taking into account the lack of cytotoxicity of TPP cation
and the absence of clear structural requirements for the
anti-proliferative activity of TPP salt, in this paper we conceived
TPP-derivatives containing protected phenol functionality.
Phenols normally act as antioxidants by scavenging free radicals
with the formation of stable phenolic radical, but they could
also become pro-oxidants and cytotoxic (Prochazkova et al.,
2011). Some phenol derivatives structurally related to chromanol
(the phenolic part of tocopherol) exhibit cancer preventive,
anti-proliferative, and pro-apoptotic antitumor activity in
xenograft tumor (Kunnumakkara et al., 2010; Ju et al., 2010; Li
et al., 2011). The exact mechanisms of action of these derivatives
remain unknown; however, various models have been put forth,
ranging from their antioxidant and anti-inflammatory effects to
altered redox-signaling (Azzi et al., 2002).
On these bases, we designed and synthetized two phenol
TPP-derivatives (Figure 1) where hydroxyl groups are protected
as esters, able to accumulate in mitochondria and release the
corresponding phenols by enzymatic hydrolysis. We investigated
the cytotoxic activity of these compounds against different cancer
cell lines and normal cells, and the biochemical mechanisms of
their selective anti-cancer activity.
MATERIALS AND METHODS
Chemicals
Fetal bovine serum and culture medium were from Invitrogen
Life Technologies (Carlsbad, CA, United States). Plasticware
for cell cultures was from Falcon (Becton Dickinson, Franklin
Lakes, NJ, United States). The protein content in cell monolayers
and mitochondrial extracts was assessed with the BCA kit from
Sigma Chemical Co. (St. Louis, MO, United States). TPMP was
FIGURE 1 | Phenolic esters TPP-derivatives.
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purchased from TCI Europe N.V. (Zwijndrech, Belgium). Unless
otherwise specified, all the other reagents were purchased from
Sigma Chemical Co.
Lipophilicity Measurements
The partition coefficient between n-octanol and PBS at pH
7.4 (log P) was obtained by shake-flask technique at room
temperature. In the shake flask experiments 50 mM PBS pH
7.4 was used as aqueous phase; the organic (n-octanol) and
aqueous phase (PBS) were mutually saturated by shaking for
4 h. The compounds were solubilised in the buffered aqueous
phase at a concentration of 30 µg/ml and appropriate amounts
of n-octanol were added. The two phases were shaken for
about 20 min, by which time the partitioning equilibrium of
solutes is reached, and then centrifuged (10000 rpm, 10 min).
The concentration of the solutes was measured in the aqueous
phase by UV spectrophotometer (UV-2501PC, Shimadzu); the
values of absorbance (223, 268 and 275 nm) were interpolated
in calibration curves obtained using standard solutions of
compounds (concentration range 30–0.5 µg/ml; r2 > 0.99). Each
log P-value is an average of at least six measurement.
Cells
Human colon cancer HT29 cells, colon-derived normal
fibroblast CCD-18Co cells, lung cancer A549 cells, normal
human bronchial epithelial (immortalized with adenovirus
12-SV40 virus hybrid Ad12SV40) BEAS-2B cells, breast cancer
MDA-MB-231 cells, normal breast epithelial MCF10A cells,
human osteosarcoma U-2OS cells were purchased from ATCC
(Manassas, VA, United States). Primary osteoblasts were
generated as reported previously (Buondonno et al., 2016).
HMM and HMC were primary cells stabilized in culture as
described (Aldieri et al., 2004). The use of primary cells was
approved by Ethical Committee of the San Luigi Gonzaga
Hospital, Orbassano, (protocol #126/2016). All subjects gave
written informed consent in accordance with the Declaration of
Helsinki. Cells were maintained in medium supplemented with
10% v/v fetal bovine serum, 1% v/v penicillin-streptomycin, 1%
v/v L-glutamine. Morphological analysis was performed with a
bright field microscope (Leica Microsystems, Wetzlar, Germany).
At least 5 fields/experimental condition were examined.
Mitochondria Isolation
Mitochondria were isolated as reported (Riganti et al., 2013a).
To isolate mitochondrial fractions, 5 × 106 cells were washed
twice in ice-cold PBS, then lysed in 0.5 ml buffer A (50 mM Tris,
100 mM KCl, 5 mM MgCl2, 1.8 mM ATP, 1 mM EDTA; pH 7.2),
supplemented with protease inhibitor cocktail III (Calbiochem.
La Jolla, CA, United States), 1 mM phenylmethylsulfonyl fluoride
and 250 mM NaF. Samples were clarified by centrifuging at
650 × g for 3 min at 4◦C. The supernatant was collected and
centrifuged at 13,000 × g for 5 min at 4◦C. This supernatant,
containing the cytosolic fraction, was stored at −80◦C until
the use. The pellet containing mitochondria was washed in
0.5 ml buffer A and re-suspended in 0.25 ml buffer B (250 mM
sucrose, 15 mM K2HPO4, 2 mM MgCl2, 0.5 mM EDTA,
5% w/v, BSA). A 50 µl aliquot was sonicated and used for
the measurement of protein content or Western blotting; the
remaining part was stored at −80◦C until the use. To confirm
the presence of mitochondrial proteins in the extracts and the
absence of cytosolic contamination in the mitochondrial fraction,
10 µg of each sonicated sample were subjected to SDS–PAGE
and probed with an anti-porin antibody (Abcam, Cambridge,
United Kingdom), a mitochondrial marker, and with an anti-
glyceraldehyde 3-phosphate dehydrogenase antibody (GAPDH;
Santa Cruz Biotechnology Inc., Santa Cruz, CA, United States),
a cytosolic marker. Mitochondrial extracts were used only if
they had detectable levels of porin and undetectable levels
of GAPDH. To exclude any mitochondrial contamination in
the cytosolic extracts, the absence of porin and the presence
of GAPDH in the latter was analyzed by Western blotting
(Supplementary Figure S1). Nuclear proteins were extracted
using the Nuclear Extract Kit (Active Motif, La Hulpe, Belgium).
10 µg of nuclear extracts were subjected to SDS–PAGE and
probed with antibodies against: proliferator-activated receptor
gamma coactivator 1-α (PGC-1α; Abcam), an index of increased
mitochondrial biogenesis (Buondonno et al., 2016), or TATA box
Binding Protein (TBP; Santa Cruz Biotechnology Inc.), as control
of equal protein loading.
Mitochondrial/Cytosolic Distribution
The amount of 1, 2, 15, and 16 in the mitochondrial and cytosolic
fractions was determined by LC-ESI-MS analyses. LC-ESI-MS
analyses were performed with an Acquity Ultra Performance
LCTM (Waters Corporation, Milford, MA, United States),
equipped with BSM, SM, CM, and PDA detector. All the
chromatographic separations were performed on a Zorbax
Eclipse XDB-C18 (5 µm, 150 mm × 4.6 mm) (Agilent
Technologies) as a stationary phase. The supernatant samples
obtained from incubation were filtered through a 0.45 µm pore
size PTFE membrane filter before use. Aliquots (5 µl) were
injected onto the system and eluted with a mobile phase (flow
rate, 0.5 ml/min) consisting of A, 0.1% formic acid solution,
and B, acetonitrile. The following gradient was used: 0–5 min
(A = 50%, B = 50%), 5–7 min (to A = 20%, B = 80%), 7–
8 min (A = 20%, B = 80%), 8–10 min (to A = 50%, B = 50%).
The eluate was injected into the electrospray ion source (ESI),
and monitored using Micromass Quattro microTM API ESCi
multi-mode ionization Enabled as detector. MS spectra were
acquired and processed using MassLynx software. The operating
conditions on the triple quadruple mass spectrometer were as
follows: positive mode; drying gas (nitrogen) heated at 350◦C
at a flow rate of 800 l/h; nebulizer gas (nitrogen) at 80 l/h;
capillary voltage in positive mode at 3000 V; cone voltage at
30 V. The molecular ion [M]+ was employed for quantitative
measurements of analytes. The values obtained from integration
of the peak of compounds were interpolated in a calibration curve
obtained using standard solutions at 0.01 to 5 µM. The amount
of each compound in the mitochondrial and cytosolic fractions
was expressed as pmol/mg proteins.
Cytotoxicity and Viability
The extracellular release of LDH, considered an index of cell
damage and necrosis, was measured spectrophotometrically,
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as reported (Riganti et al., 2013b). The extracellular medium
was centrifuged at 12,000 × g for 15 min to pellet cellular
debris, the cells were washed with fresh medium, detached
with 0.01% trypsin/EDTA, re-suspended in 0.2 ml of 82.3 mM
triethanolamine phosphate-HCl (pH 7.6), and sonicated on ice
with two 10-sec bursts. LDH activity was measured in the
extracellular medium and in the cell lysate: 50 µl of extracellular
medium or 5 µl of cell lysate were incubated at 37◦C with 5 mM
NADH. The reaction was started by adding 20 mM pyruvic acid
and was monitored for 6 min, measuring absorbance at 340 nm
using a Synergy HT Multi-Detection Microplate Reader (Bio-
Tek Instruments, Winoosky, MT, United States). The reaction
kinetics were linear throughout the time of measurement. Both
intracellular and extracellular enzyme activities were expressed
as µmol NADH oxidized/min/dish. The results were expressed
as percentage of extracellular LDH versus total (intracellular
plus extracellular) LDH. Cell viability was measured by the
neutral red staining method, as previously reported (Riganti et al.,
2015b). The absorbance of untreated cells was considered as 100%
viability; the results were expressed as percentage of viable cells
versus untreated cells. IC50 was calculated with the CompuSyn
software1.
Mitochondrial Mass and Mitochondria
Biogenesis
The amount of proteins in mitochondrial extracts, normalized to
the total amount of cellular proteins, was considered an index of
mitochondrial mass (Jean et al., 2015). Mitochondria biogenesis
was evaluated by measuring the expressions of subunit I of
COX-I, which is encoded by mitochondrial DNA, and of the
SDH-A of complex II, which is encoded by nuclear DNA, using
the MitoBiogenesisTM In-Cell ELISA Kit (Abcam), following the
manufacturer’s instructions. The unit (U) of each protein/mg
mitochondrial proteins were calculated. Results were expressed
as COX-1/SDH-A ratio.
Confocal Microscope Analysis
0.5 × 105 cells were grown on sterile glass coverslips. 200 nM
MitoTracker R© Green FM (Invitrogen Life Technologies, Milano,
Italy) was add for 45 min. Cells were rinsed with PBS, fixed with
3.7% w/v paraformaldehyde (diluted in PBS) for 5 min, washed
three times with PBS then the slides were mounted with 10 µl of
Gel Mount Aqueous Mounting. The samples were analyzed with
an Olympus FV300 laser scanning confocal microscope equipped
with a Blue Argon (488 nm) laser, a Green Helium Neon
(543 nm) laser, and FluoView 300 software (Olympus Biosystems,
Hamburg, Germany). For each experimental conditions, 10 fields
were examined.
Electron Transport Chain
The electron transport between complexes I and III was
measured in mitochondrial extracts, immediately after extract
thawing, as detailed earlier (Jean et al., 2015). In particular,
10 µl of not-sonicated mitochondrial samples were re-suspended
1http://www.combosyn.com
in 0.59 ml buffer C (5 mM KH2PO4, 5 mM MgCl2, 5%
w/v BSA) and transferred into a quartz spectrophotometer
cuvette. Then 0.38 ml buffer D (25% w/v saponin, 50 mM
KH2PO4, 5 mM MgCl2, 5% w/v BSA, 0.12 mM cytochrome
c-oxidized form, 0.2 mM NaN3) was added for 5 min at
room temperature. The reaction was started with 0.15 mM
NADH and was followed for 5 min, reading the absorbance
at 550 nm by a Lambda 3 spectrophotometer (PerkinElmer,
Waltham, MA, United States). The results were expressed as
nmoles reduced cytochrome c/min/mg mitochondrial proteins.
As reported earlier (Wibom et al., 2002), one cycle of freezing
and thawing, following by the addition of 25% w/v saponin, did
not destroy mitochondrial membrane structure and integrity and
allowed to measure the maximal metabolic and redox capacity of
mitochondria. Therefore, this procedure was adopted to evaluate
the electron transport chain activity, the ATP and ROS levels, the
mitochondrial depolarization.
Mitochondrial ATP
The amount of ATP was measured on 20 µg of mitochondrial
extracts with the ATP Bioluminescent Assay Kit (FL-AA,
Sigma Chemical Co.). Data were converted into nmoles/mg
mitochondrial proteins, using a calibration curve previously set.
Mitochondrial ROS Measurement
The amount of ROS in mitochondrial extracts was measured
fluorimetrically by incubating cell suspension at 37◦C for
10 min with 10 µM of MitoSOX Red probe (Invitrogen
Life Technologies), as per manufacturer’s instructions. Results
were expressed as nmoles/mg mitochondrial proteins, using a
calibration curve previously set with serial dilution of H2O2.
Mitochondrial Depolarization
Mitochondrial depolarization was measured by staining cells
with the fluorescent probe JC-1 (Biotium Inc., Hayward, CA,
United States), as described (Riganti et al., 2015a). The red
fluorescence, index of polarized mitochondria, was detected at
550 nm (λ excitation) and 600 nm (λ emission); the green
fluorescence, index of depolarized and damaged mitochondria,
was detected at 485 nm (λ excitation) and 535 nm (λ emission).
The fluorescence units were used to calculate the percentage of
green-fluorescent versus red-fluorescent mitochondria.
Caspase Activity
The activity of caspase 9 and 3 was measured by incubating 20 µg
cell lysates with the respective fluorogenic substrates Ac-LEHD-
AMC (LEHD-AMC) or DEVD-AMC (DEVD-AMC), as reported
(Pinzón-Daza et al., 2012). Results were expressed as nmoles
AMC/mg protein.
Cell Cycle Analysis
1 × 104 cells were harvested, washed with PBS, treated with
0.25 mg/ml RNAse and stained for 15 min with 50 µg/ml
propidium iodide. Cell cycle distribution was analyzed by Guava R©
easyCyte flow cytometer (Millipore, Billerica, MA, United States),
using the InCyte software (Millipore).
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Statistical Analysis
All data in text and figures are provided as means+SD. The
results were analyzed by a one-way ANOVA and Tukey’s test.
p< 0.05 was considered significant.
RESULTS
Synthesis of TTP Derivatives
TPP salts were obtained as described in Figure 2. 4-
Hydroxybenzaldehydes (3, 4) were acylated using acetyl
chloride or benzoyl chloride, giving corresponding
4-acyloxybenzaldehydes (5, 6). The subsequent reduction
of aldehyde with NaBH4, followed by the treating with NBS and
Ph3P, gave benzyl bromide derivatives 7 and 8. Finally, alkylation
of triphenylphosphine in toluene solution afforded desired
TPP-derivatives 1 and 2.
References phenols were obtained following the similar
synthetic strategy, using tert-butyl carbonate as a protecting
group. The deprotection of tert-butyloxycarbonyl derivatives by
action of HBr 48% in methanol afforded 4-hydroxybenzyl TPP
bromides 15 and 16.
Lipophilicity Measurements
The partition coefficient (log P) of compounds 1 and 2, as
well as their parent phenols 15 and 16, were measured in
n-octanol/PBS system using shake-flask techniques (Table 1).
All the compounds were quite lipophilic despite the presence
of cationic TPP moieties. As expected, the log P-values of
phenolic esters 1 and 2 were higher with respect to the parent
phenols 15 and 16, but these differences are not high enough
to hypothesize the partial ionization of hydroxyl group at pH
7.4. Log P-values are close to the optimal range for the passive
membrane penetration that should permit good intracellular
accumulation of our derivatives.
Phenol TPP-Derivatives Are Effective
Against a Broad Spectrum of Tumor Cells
We first screened the cytotoxic effects of different concentrations
of our TPP-derivatives, measured as release of LDH in the
extracellular medium after 24 h. We analyzed a panel of human
cancer cell lines of different histological origin and normal cells
of the same organ. As shown in Figure 3, both compounds (1
and 2) induced a dose-dependent increase of extracellular LDH,
either in cancer cell lines and normal cells. Consistently, the cell
viability after prolonged exposure (72 h) was dose-dependently
reduced (Figure 4).
To obtain a most precise quantitative measure of the
differential cytotoxicity exerted by compound 1 and 2 in cancer
cell lines and normal cells, and to better compare the products,
we calculated the IC50 for these TPP-derivatives in all the cell
lines examined (Table 2). Notwithstanding the great variability
among each cell line, in all cancer cell lines the IC50 for both
compounds was below 10 µM. With the exception of the breast
cancer/mammary epithelium pair (i.e., MDA-MB-231/MCF10A
cells) for compound 1, the IC50 was lower in cancer cell lines
than in normal cells for both compounds. In lung cancer A549
cells and in osteosarcoma U-2OS cells, the IC50 was below 1 µM,
a value in line with several chemotherapeutic drugs. The ratio
between the IC50 in BEAS-2B cells and A549 cells was 16.97 for
compound 1 and 13.38 for compound 2, respectively. The ratio
between the IC50 in osteoblasts and U-2OS cells was 14.36 for
compound 1 and 5.41 for compound 2, respectively. Overall,
these results confirmed that compounds 1 and 2 showed a
generally higher cytotoxicity against cancer cell lines than against
normal cells. According to the IC50 values, the best cancer cell
models, candidate to be treated with the TPP-derivatives were
lung cancer and osteosarcoma. Since the lung cancer/normal lung
epithelium pair displayed the highest differences between the
IC50 for both compounds, we focused on this model to investigate
the mechanisms of this preferential cytotoxicity.
Phenolic Esters TPP-Derivatives
Accumulate in Mitochondria and Are
Hydrolyzed to the Corresponding
Phenols
As shown in the Supplementary Figure S2, TPMP (i.e., TPP
moiety only) did not reduce viability of A549 and BEAS-2B cells,
suggesting that cytotoxic effect is due to the TPP-derivatives 1
and 2.
Since TPP moiety is a well-known cation crossing the
mitochondrial membranes (Rideout et al., 1989; Bergeron et al.,
2009), we first measured the intra-mitochondrial accumulation of
these compounds.
FIGURE 2 | Synthesis of designed TPP-derivatives and TPP-substituted phenols. Reagents and conditions: (i) R”COCl, Et3N, CH2Cl2, 0◦C, or Boc2O, DMAP,
CH2Cl2, 0 ◦C; (ii) NaBH4, MeOH, 0 ◦C; (iii) NBS, PPh3, CH2Cl2, 0 ◦C; (iv) PPh3, toluene, reflux; (v) HBr 48% in MeOH, rt.
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TABLE 1 | aLipophilicity measurement of phenol TPP-derivatives.
Compound log P ( ± SD)
1 0.64 ( ± 0.09)
2 3.15 ( ± 0.08)
15 0.50 ( ± 0.06)
16 1.02 ( ± 0.06)
aEach log P-value is an average of at least six measurement.
The intra-mitochondrial accumulation of esters 1 and 2 as
well as their parent phenols 15 and 16 were evaluated using
LC-MS technique, by incubating A549 and BEAS-2B cells with
0.1 and 1 µM solutions as detailed in the Materials and Methods
section. After a 4 h incubation, the cellular mitochondrial and
cytosolic fractions were separated and the amount of 1, 2,
15, and 16 in the two fractions was measured by UPLC with
mass detector. As shown in Figure 5 both TPP esters 1 and
2 penetrate in good extent in A549 cells (Figures 5A,B, Left),
while their concentration in BEAS-2B cells was at least ten fold
lower (Figures 5A,B, Right), in line with their toxicity profile.
Only phenol derivative 15 was detected after incubation with 1
(Figure 5A): this result confirms the accumulation of compound
1 with a further fast hydrolysis into phenol 15. The cytosolic
concentration of 15 after incubation with 0.1 µM of 1 was below
detection limit, while mitochondrial accumulation was easily
detectable. Even after incubation at 1 µM of 1 the cytosolic
concentration of 15 was very low. The derivative 2 has a bit
different behavior: benzoic ester seems to be more stable with
respect to acetate, though both benzoate 2 and corresponding
phenol 16 were detected after 4 h of incubation with 2
(Figure 5B). Also in this case the compounds accumulate almost
exclusively at mitochondrial level, and A549 cells accumulated
significantly more TPP-derivatives than BEAS-2B cells.
To verify whether also 15 and 16 entered into the cells,
we directly incubated A549 and BEAS-2B cells with these two
phenol TPP-derivatives. The intracellular concentration found
was very low in both cell lines for either 15 (Figure 5C) and 16
(Figure 5D). Such low intracellular accumulation could explain
the lack of toxicity of 15 and 16: indeed compounds 15 and 16
did not increase the release of LDH (Supplementary Figure S3A)
nor reduced cell viability (Supplementary Figure S3B) when
incubated on A549 and BEAS-2B cells. These results exclude
that the presence of compounds 15 and 16 in the extracellular
environment induce cytotoxicity; however, we cannot exclude
a priori that they can elicit toxicity once generated inside the cell.
Phenol TPP-Derivatives Impair
Mitochondrial Energetic Metabolism and
Trigger Mitochondria-Dependent
Apoptosis in Tumor Cells
Compared to BEAS-2B, A549 cells had a higher mitochondrial
mass, measured on the basis of mitochondrial proteins (Jean
et al., 2015) (Figure 6A) and a higher rate of mitochondrial
biogenesis, indicated by the higher ratio between COX-I, which is
encoded by mitochondrial DNA, and SDH-A, which is encoded
by nuclear DNA (Figure 6B). Consistently, the transcription
factor PGC-1α, a master regulator of mitobiogenesis (Buondonno
et al., 2016), was constitutively translocated into the nucleus (i.e.,
activated) in A549 cells, but its nuclear level was reduced by
compounds 1 and 2. BEAS-2B cells had lower levels of nuclear
PGC-1α, that was unaffected by TPP-derivatives (Figure 6C).
The staining with Mitotracker Green indicated that A549 cells
had higher mitochondrial mass than BEAS-2B. Compounds 1
and 2 reduced the mitochondrial mass in the former but not
in the latter. The peri-nuclear distribution of mitochondria was
not changed by the TPP-derivatives, that produced, however, a
generalized decrease in the mitochondrial amount of A549 cells
(Figure 6D). To verify whether TPP-derivatives also determined
changes in mitochondrial fusion/fission, we measured the
expression of mitofusin 1 (MFN1) and mitofusin 2 (MFN2):
no changes in the expression of these genes were detected
in A549 and BEAS-2B cells, untreated or treated with TPP-
derivatives (Supplementary Figure S4), excluding an effect of the
compounds on mitochondrial fusion.
The rate of electron transport (Figure 6E) and the amount
of mitochondrial ATP (Figure 6F) were higher in A549 cells.
Compounds 1 and 2 produced a significant decrease of these
parameters in A549 cells, not in BEAS-2B cells, likely as a
consequence of the higher amount of mitochondria, where the
compounds were accumulated, and the higher baseline values of
mitochondrial energy metabolism of the former.
Higher is the electron flux, higher is the possibility to
produce ROS because of uncomplete reduction of O2, the
electrons final acceptor, or redox cycle at complex I and
III (Mailloux and Harper, 2012). At high concentrations,
ROS damage mitochondria lipids and proteins, open the
membrane permeability transition pore and promote the
cytosolic release of cytochrome c, which in turn triggers
the activation of caspase 9 and 3, producing a necro-
apoptotic death (Indran et al., 2011). In keeping with these
observations, we detected basally lower levels of mitochondrial
ROS (Figure 6G) and depolarized/damaged mitochondria
(Figure 6H) in BEAS-2B compared to A549 cells. In both cell
lines, however, the activity of caspase 9 and 3 was similar
(Figures 7A,B).
In A549 cells compounds 1 and 2 acutely increased
the mitochondrial ROS (Figure 6G) and the percentage of
depolarized mitochondria (Figure 6H), triggering a strong
activation of caspase 9 and 3 (Figures 7A,B). Again, the
compounds exerted negligible modifications of ROS (Figure 6G)
and mitochondrial depolarization (Figure 6H) in BEAS-2B cells,
where the activity of caspase 3 and 9 remained similar to
untreated cells (Figures 7A,B).
To prove that mitochondrial ROS were the inducers of
cytotoxicity, we measured the viability of cells treated with
compounds 1 or 2, in the presence or absence of MitoTempol,
a specific scavenger of ROS of mitochondrial origin (Trnka et al.,
2009). As shown in the Supplementary Figure S5, MitoTempol
alone did not affect A549 and BEAS-2B cells viability, but it
significantly prevented the reduction in cell viability induced
by compound 1 and 2 in A549 cells. By contrast, no effects
were exerted in BEAS-2B cells, where the TPP-derivatives did
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FIGURE 3 | Cytotoxicity in different cancer cell lines and normal cells. Cells were incubated 24 h in fresh medium (0) or with increasing concentrations (0.1, 1, and
10 µM) of 1 and 2. The release of LDH was measured spectrophotometrically in duplicates. Data are means ± SD (n = 3). ∗p < 0.01 vs. cells grown in fresh medium.
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FIGURE 4 | Effects of phenolic TPP-derivatives on the viability of cancer cell lines and normal cells. Cells were incubated 72 h in fresh medium (0) or with increasing
concentrations (0.1, 1, and 10 µM) of 1 and 2. Cell viability was measured spectrophotometrically in quadruplicates. Data are means ± SD (n = 3). ∗p < 0.05 vs.
cells grown in fresh medium.
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TABLE 2 | IC50 (µM) of phenol TPP-derivatives.
Cell line IC50 (µM) of 1 IC50 (µM) of 2
HT29 4.45 ± 0.78∗ 3.81 ± 0.47∗
CCD-18Co 18.21 ± 1.29 7.89 ± 0.36
A549 0.31 ± 0.09∗ 0.55 ± 0.07∗
BEAS-2B 5.26 ± 0.25 7.36 ± 0.45
MDA-MB-231 8.32 ± 1.25 0.34 ± 0.11∗
MCF10A 7.52 ± 0.43 6.32 ± 0.41
U-2OS 0.45 ± 0.16∗ 0.63 ± 0.10∗
Osteoblasts 6.46 ± 0.83 3.41 ± 0.73
HMM 4.39 ± 0.35∗ 0.82 ± 0.07∗
HMC 7.37 ± 0.89 39.09 ± 4.34
1 × 104 cells were seeded in quadruplicate in 96-well plates, treated at scalar
concentrations (from 10−10 to 10−3 M) of each compounds for 72 h, then stained
with neutral red solution. IC50 was calculated with the CompuSyn software. Data
are means ± SD (n = 4). Cancer cell lines (HT29, A549, MDA-MB-231, U-2OS,
HMM) vs. normal cells of the same organ (CCD-18Co, BEAS-2B, MCF10A, HMC):
∗p < 0.05.
not increase mitochondrial ROS (Figure 6G) and did not lower
viability (Figure 4).
Consistently with the increased activity of caspases,
compounds 1 and 2 increased the percentage of A549 cells
in the sub-Go phase, indicating a higher percentage of apoptotic
cells. This event was paralleled by a reduced percentage of cells
in S-phase, suggesting decreased proliferation (Figure 7C). By
contrast, no change in cell cycle distribution was noticed in
not-transformed BEAS-2B cells (Figure 7D), in keeping with the
absent activation of caspases. Morphological studies revealed
that, compared with untreated cells, A549 cells exposed to
compounds 1 or 2 showed a reduced cell number and a clear
round-shaped morphology, suggestive of apoptosis (Figure 7E).
BEAS-2B cells treated with TPP-derivatives only showed a
decreased cell density without appreciable morphological signs
of apoptosis (Figure 7E).
DISCUSSION
By performing a screening on a panel of human tumor
and not-transformed cells, we identified two TPP-phenol
derivatives (1 and 2) that displayed cytotoxic activity and
reduced cell viability of cancer cell lines in vitro, in keeping
with previous observations reporting antitumor activity of
TPP salts (Rideout et al., 1989; Manetta et al., 1996). Both
TPP-phenol derivatives were endorsed with cytotoxic activity
at low micromolar/submicromolar (0.1–1 µM) concentrations.
This efficacy was similar to the antitumor activity of the most
effective TPP salts, selected over a library of 40000 candidates
(Millard et al., 2010). Of note, the reduced viability was achieved
in all the cancer cell lines, independently of the histological origin,
although different cancer cell lines exhibited different IC50 to the
compounds. This finding suggests that the compounds exert their
cytotoxic effects exploiting biochemical mechanisms that are
common to all cancer cell lines tested. Another key feature of the
phenol TPP-derivatives synthesized is that the anti-proliferative
effect appeared lower - comparing the same concentration and
incubation time - in normal cells.
To investigate the biochemical mechanisms that may explain
the cytotoxic efficacy of the phenol TPP-derivatives and their
greater potential against tumor cells, we focused on the lung
cancer/normal lung epithelium pair, which displayed the highest
differences between the cytotoxicity of both compounds.
Since TPP cation is a well-known vector for the mitochondria
(Rideout et al., 1989; Bergeron et al., 2009), we first evaluated the
intra-mitochondrial accumulation of these compounds, finding
that our phenolic esters 1 and 2 accumulate in mitochondria and
produce phenols 15 and 16 with different kinetics. Compounds 1
and 2 accumulation in normal cells was significantly lower than
in cancer cells.
The high intra-mitochondrial accumulation of our TPP-
derivatives prompted us to investigate if they may interfere with
the mitochondrial energetic metabolism and redox balance, two
processes that – when altered – reduce cancer cell proliferation
and trigger apoptosis (Trotta and Chipuk, 2017).
Consistent with experimental observations demonstrating
that mitochondria play a key role in sustaining tumor energetic
demand (Caino et al., 2015; Trotta and Chipuk, 2017; García-
Ledo et al., 2017), A549 cells had a significantly higher
mitochondrial mass and energetic metabolism. This phenotype
is likely due to the increased mitobiogenesis sustained by the
constitutive activation of PGC-1α in A549 cells. By reducing
the active PGC-1α, the amount of mitochondria and the
ability to synthesize ATP via the electron transport chain,
compounds 1 and 2 interfered with the key compartments that
provide cancer cells with the necessary fuel. It is generally
accepted that the transmembrane potential of normal cells is less
negative, suggesting a lower energetic activity of mitochondria in
not-tumor tissues (Modica-Napolitano and Aprille, 2001). This
finding - that was confirmed by comparing BEAS-2B cells with
A549 cells - may explain why the effects of 1 and 2 were negligible
in BEAS-2B cells. Since the lower potential of mitochondrial
membrane in normal cells theoretically also reduces the delivery
of phenol TPP-derivatives into mitochondria of these cells, we
might speculate that the absence of metabolic effects in BEAS-2B
can be due to the lower mitochondrial accumulation of 1 and 2.
In addition BEAS-2B cells had a lower PGC-1α activation that
may result in reduced mitobiogenesis and mitochondrial mass.
All these events, strongly reduced by TPP-derivatives in A549
cells, were not modified in BEAS-2B cells.
Whatever the mechanism can be, the higher derangement of
mitochondrial metabolism in cancer cells and the absence of
effects in normal cells, make phenol TPP- derivatives promising
cancer cell-selective compounds, unveiling a property that is
uncommon for most chemotherapeutic drugs.
Notwithstanding A549 cells displayed a higher proton
motive-force coupled with higher intra-mitochondrial ROS
levels, this situation did not induce mitochondrial depolarization
or mitochondrial-triggered apoptosis. Cancer cells have high
levels of anti-oxidant enzymes, including the mitochondrial
superoxide dismutase 2, that may buffer ROS more efficiently
than in non-transformed cells (Idelchik et al., 2017). On
the other hand, low levels of mitochondrial ROS are known
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FIGURE 5 | Intra-mitochondrial and cytosolic accumulation of TPP-derivatives. (A) A549 (Left) and BEAS-2B (Right) cells were incubated 4 h with two different
concentrations (0.1 and 1 µM) of 1. (B) A549 (Left) and BEAS-2B (Right) cells were incubated 4 h with two different concentrations (0.1 and 1 µM) of 2. (C) A549
(Left) and BEAS-2B (Right) cells were incubated 4 h with two different concentrations (0.1 and 1 µM) of 15. (D) A549 (Left) and BEAS-2B (Right) cells were incubated
4 h with two different concentrations (0.1 and 1 µM) of 16. The concentration of 1, 2, 15, and 16 in mitochondrial and cytosolic fractions were measured using
LC-MS techniques. Data are means ± SD (n = 3). ∗p < 0.01: mitochondria vs. cytosol. ∗∗p < 0.001: A549 vs. BEAS-2B in all the corresponding conditions (A,B);
∗p < 0.05: A549 vs. BEAS-2B in all the corresponding conditions (C); ∗p < 0.05: A549 vs. BEAS-2B (cytosolic fraction, 1 µM conventration (D).
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FIGURE 6 | Effects of phenol TPP-derivatives on mitochondria metabolism. A549 and BEAS-2B cells were incubated 4 h in fresh medium (ctrl) or in medium
containing 0.1 µM of 1 and 2. After the separation of mitochondria and cytosol extracts, the following assays were performed. (A) Mitochondrial proteins were
measured spectrophotometrically in duplicates. Data are means ± SD (n = 3). ∗p < 0.001 vs. A549 ctrl cells; ◦p < 0.001 for BEAS-2B cells vs. the corresponding
condition in A549 cells. (B) Mitobiogenesis was measured by ELISA, in duplicates. Data are means ± SD (n = 3). ∗p < 0.001 vs. A549 ctrl cells; ◦p < 0.002 for
BEAS-2B cells vs. the corresponding condition in A549 cells. (C) Immunoblot analysis of PGC-1α and TBP in nuclear extracts. The blot is representative of one out
(Continued)
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FIGURE 6 | Continued
of three experiments with similar results. (D) Confocal analysis of mitochondrial staining with MitoTracker R© Green FM. Magnification: 60 × objective (0.52 numerical
aperture); 10 × ocular lens. Bar: 10 µM. The micrographs are representative of three experiments with similar results. (E,F) The electron transport was measured
spectrophotometrically in duplicates. ATP levels in mitochondrial extracts was measured by a chemiluminescence-based assay, in duplicates. Data are means ± SD
(n = 3). For both panels: ∗p < 0.001 vs. A549 ctrl cells; ◦p < 0.001 for BEAS-2B cells vs. the corresponding condition in A549 cells. (G,H) ROS amount in
mitochondrial extracts and mitochondrial damage were measured fluorimetrically, in duplicates. Data are means ± SD (n = 3). For both panels: ∗p < 0.001 vs. A549
ctrl cells; ◦p < 0.001 for BEAS-2B cells vs. the corresponding condition in A549 cells. There were no statistically significant differences between untreated (ctrl) and
compound 1/compound 2-treated BEAS-2B cells for all the parameters analyzed in this figure.
FIGURE 7 | Effects of phenol TPP-derivatives on mitochondria-dependent apoptosis. A549 and BEAS-2B cells were incubated 24 h in fresh medium (ctrl) or in
medium containing 0.1 µM of 1 or 2. (A,B) The activity of caspase 9 and 3 was measured fluorimetrically, in duplicates. Data are means ± SD (n = 3). For both
panels: ∗p < 0.001 vs. A549 ctrl cells; ◦p < 0.001 for BEAS-2B cells vs. the corresponding condition in A549 cells. (C,D) Cell cycle distribution, measured in
duplicates. Data are means ± SD (n = 3). For both panels: ∗p < 0.001 vs. A549 ctrl cells: ◦p < 0.001 for BEAS-2B cells vs. the corresponding condition in A549
cells. (E) Bright field microscope analysis of cells. Magnification: 60 × objective (0.52 numerical aperture); 10 × ocular lens. Bar: 20 µM. The micrographs are
representative of three experiments with similar results.
to promote oncogenic pro-survival pathways (Idelchik et al.,
2017) and to train cancer cells to a better adaptation to
stressing conditions that prevent cell damage, a process known
as mitohormesis (Yun and Finkel, 2014). Only a significant
increase in ROS levels may overcome anti-oxidant defenses and
mitohormetic adaptation, triggering cell death instead of cell
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survival mechanisms (Idelchik et al., 2017; Yun and Finkel,
2014).
This is indeed what happened in A549 cells treated with 1
and 2, that increased the amount of intra-mitochondrial ROS
and damaged mitochondria, inducing the activation of caspase
9 and 3 and increasing apoptosis. Since MitoTempol, a specific
scavenger of mitochondrial ROS, prevented the reduction in
viability induced by 1 and 2, it is likely that the cytotoxic effect
of the TPP-derivatives was due to the increase in mitochondrial
ROS in this cancer cell line. Again, all these effects were absent in
BEAS-2B cells, where the baseline mitochondrial metabolism was
lower and not altered by 1 and 2.
Of note, A549 cells and U-2OS cells, the two cell lines that
displayed the higher cytotoxicity exerted by compounds 1 and
2, had higher values of electron transport chain, compared to
HT29 and MDA-MB-231 cells, where the compounds were less
effective. Indeed the rate of electron chain transport was 10.41
+ 0.72 nmoles reduced cytochrome c/min/mg mitochondrial
proteins in A549 cells (Figure 6C), 6.58 + 0.51 nmoles reduced
cytochrome c/min/mg mitochondrial proteins – corresponding
to an oxygen consumption rate of 620 + 44 pmoles/min -
in U-2OS cells (Buondonno et al., 2016), 2.37 + 0.45 nmoles
reduced cytochrome c/min/mg mitochondrial proteins in HT29
cells (Riganti et al., 2013a), 2.11 + 0.275 nmoles reduced
cytochrome c/min/mg mitochondrial proteins in MDA-MB-231
cells (Gazzano et al., 2018). These observations may explain
the differential cytotoxic effects of the TPP-derivatives among
different cancer cell lines, suggesting that the compounds are
more effective against cancer cells with a higher mitochondrial
energy metabolism. On the other hand, we cannot exclude
that other mechanisms, such as a different intracellular and/or
intramitochondrial accumulation of the compounds, may explain
the different efficacy in different cell lines. Ongoing screenings
at our laboratory on a larger panel of cancer cell lines with
different rates of electron transport chain will clarify this
point.
Collectively, these results reinforce the evidences that
compound 1 and 2 exert a preferential cytotoxic effect in cancer
cells. This feature may be due to at least two reasons. First, cancer
cells had higher basal mitobiogenesis than normal cells, likely due
to the constitutively activation of PGC-1α, and compounds 1 and
2 reduced these events in cancer cells but not in normal cells.
Second, the high accumulation of compounds 1 and 2 and their
metabolites within mitochondria, impaired the mitochondrial
energy metabolism and increased the synthesis of ROS, that
induced a mitochondrial damage and triggered the caspase
9/caspase 3-dependent apoptosis.
Despite a reduction in the cell number of BEAS-2B cells,
compounds 1 and 2 did not exert significant effects on cell cycle
progression, apoptosis or LDH release. Most importantly, the
compounds did not affect cell viability of normal cells after 72 h.
On the basis of these results, we may hypothesize that TPP-
derivatives induced a cytostatic effect at short time in normal
cells that are however able to recover and survive. By contrast,
compounds 1 and 2 induced an irreversible mitochondrial
damage of cancer cells that trigger apoptosis and reduced cell
viability. The different targeting of mitochondrial metabolisms in
cancer and normal cells may explain such differential behavior.
We are aware that the in vitro experiments cannot guarantee
that the compounds are safe for healthy tissues, since these
data can be obtained only by in vivo experiments. However, the
higher intracellular and intra-mitochondrial accumulation, and
the higher derangement of mitochondrial energetic and redox
metabolism induced by TPP-derivatives in cancer cells versus
normal cells are good premises to study the compounds in
preclinical models to ascertain the real safety for healthy tissues
and the existence of a suitable therapeutic window, exploitable in
clinical settings.
CONCLUSION
We developed two phenolic esters TPP-derivatives that have
higher cytotoxicity against cancer cells than against normal cells.
The reasons of such efficacy and selectivity are the high intra-
mitochondrial accumulation of the compounds and their ability
to impair a metabolic phenotype of cancer cells, i.e., the high
mitochondrial metabolism that is vital to meet the energetic
demand of cancer cells. The events induced by phenol TPP-
derivatives reproduce what we already observed in cancer cells
treated with doxorubicin-derivatives vectorised to mitochondria,
that impair mitochondrial energy metabolism, increase intra-
mitochondrial ROS, trigger mitochondrial depolarization, and
apoptosis (Riganti et al., 2015a; Buondonno et al., 2016). These
data suggest that – independently of the structure – drugs that
interfere with mitochondrial functions are promising anti-cancer
tools.
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